Skip to main content
Erschienen in: Rheumatology International 2/2021

23.10.2020 | Case Based Review

Giant cell arteritis associated with inflammatory bowel disease: a case-series and review of the literature

verfasst von: Delamo I. Bekele, Kenneth J. Warrington, Matthew J. Koster

Erschienen in: Rheumatology International | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

To describe the clinical characteristics, management, and outcome of a series of patients with giant cell arteritis (GCA) and inflammatory bowel disease (IBD). Patients with both GCA and IBD evaluated between 1/1/1996 and 12/30/2018 were retrospectively identified. Clinical characteristics, laboratory parameters, radiologic features, histopathology, management and outcomes were abstracted. A systematic literature review identifying patients with IBD and GCA was performed via a Medline and EMBASE search from inception through December 31 2019. Six patients were identified with GCA and IBD (66% male). Five (83%) had ulcerative colitis (UC) and one had Crohn’s disease (CD). Diagnosis of IBD preceded GCA in four patients with an average interval of 30 years (range 14–42). Average time to IBD diagnosis in those with prior GCA diagnosis was 1.5 years. During mean follow-up of 4.3 years, GCA relapse was infrequent with only one patient with relapse observed. Systematic literature review identified six additional patients with confirmed coexistence of GCA and IBD. Similar to the current series, male sex was more common and ulcerative colitis was the predominant IBD phenotype. The current study reports findings from the largest single-institution case-series of co-existent GCA and IBD. In contrast to Takayasu arteritis with co-existent IBD, which displays a predilection for female sex and Crohn’s disease phenotype, both the current study and review of literature demonstrate a stronger association of GCA with male sex and ulcerative colitis. Further studies addressing a potential pathophysiologic connection between GCA and IBD are suggested.
Literatur
1.
Zurück zum Zitat Wilson JC et al (2015) Inflammatory bowel disease and the risk of autoimmune diseases. J Crohn’s Colitis 10(2):186–193CrossRef Wilson JC et al (2015) Inflammatory bowel disease and the risk of autoimmune diseases. J Crohn’s Colitis 10(2):186–193CrossRef
2.
Zurück zum Zitat Cohen R et al (2008) Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001–2002. Inflamm Bowel Dis 14(6):738–743CrossRef Cohen R et al (2008) Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001–2002. Inflamm Bowel Dis 14(6):738–743CrossRef
3.
Zurück zum Zitat Halling ML et al (2017) Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol 23(33):6137–6146CrossRef Halling ML et al (2017) Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol 23(33):6137–6146CrossRef
4.
Zurück zum Zitat Sy A et al (2016) Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature. Semin Arthritis Rheum 45(4):475–482CrossRef Sy A et al (2016) Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature. Semin Arthritis Rheum 45(4):475–482CrossRef
5.
Zurück zum Zitat Yavne Y et al (2018) Giant cell arteritis and inflammatory bowel disease - Is there a connection? Results from a population-based study. Autoimmun Rev 17(11):1134–1137CrossRef Yavne Y et al (2018) Giant cell arteritis and inflammatory bowel disease - Is there a connection? Results from a population-based study. Autoimmun Rev 17(11):1134–1137CrossRef
6.
Zurück zum Zitat Bernstein CN et al (2016) World gastroenterology organisation global guidelines inflammatory bowel disease: update August 2015. J Clin Gastroenterol 50(10):803–818CrossRef Bernstein CN et al (2016) World gastroenterology organisation global guidelines inflammatory bowel disease: update August 2015. J Clin Gastroenterol 50(10):803–818CrossRef
7.
Zurück zum Zitat Hunder GG et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128CrossRef Hunder GG et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128CrossRef
8.
Zurück zum Zitat Ronchetto F, Pistono PG (1993) Temporal arteritis in a patient with ulcerative colitis. Coincidental association or (immuno) pathogenetic link? Recent Prog Med 84(1):54–56 Ronchetto F, Pistono PG (1993) Temporal arteritis in a patient with ulcerative colitis. Coincidental association or (immuno) pathogenetic link? Recent Prog Med 84(1):54–56
9.
Zurück zum Zitat Gobron C et al (2010) Unilateral carotid granulomatous arteritis and Crohn's disease. 166(5):542–546. Gobron C et al (2010) Unilateral carotid granulomatous arteritis and Crohn's disease. 166(5):542–546.
10.
Zurück zum Zitat Jacob A et al (1990) Ulcerative colitis and giant cell arteritis associated with sensorineural deafness. J Laryngol Otol 104(11):889–890CrossRef Jacob A et al (1990) Ulcerative colitis and giant cell arteritis associated with sensorineural deafness. J Laryngol Otol 104(11):889–890CrossRef
11.
Zurück zum Zitat Sanges S et al (2016) Giant cell arteritis and ulcerative colitis: an unusual association. Semin Arthritis Rheum 46(1):e3-5CrossRef Sanges S et al (2016) Giant cell arteritis and ulcerative colitis: an unusual association. Semin Arthritis Rheum 46(1):e3-5CrossRef
12.
Zurück zum Zitat Watanabe R et al (2016) Giant cell arteritis: from pathogenesis to therapeutic management. Curr Treatm Opt Rheumatol 2(2):126–137CrossRef Watanabe R et al (2016) Giant cell arteritis: from pathogenesis to therapeutic management. Curr Treatm Opt Rheumatol 2(2):126–137CrossRef
13.
Zurück zum Zitat Chandran AK et al (2015) The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950–2009. Scand J Rheumatol 44(3):215–218CrossRef Chandran AK et al (2015) The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950–2009. Scand J Rheumatol 44(3):215–218CrossRef
14.
Zurück zum Zitat Labarca C et al (2016) Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 55(2):347–356CrossRef Labarca C et al (2016) Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 55(2):347–356CrossRef
15.
Zurück zum Zitat Martinez-Lado L et al (2011) Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 90(3):186–193CrossRef Martinez-Lado L et al (2011) Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 90(3):186–193CrossRef
16.
Zurück zum Zitat Koster MJ et al (2019) Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study. J Rheumatol 46(5):501–508CrossRef Koster MJ et al (2019) Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study. J Rheumatol 46(5):501–508CrossRef
17.
Zurück zum Zitat Mahr AD et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789–2797CrossRef Mahr AD et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789–2797CrossRef
18.
Zurück zum Zitat Koster MJ et al (2018) Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology 57(suppl_2):ii32-ii42 Koster MJ et al (2018) Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology 57(suppl_2):ii32-ii42
19.
Zurück zum Zitat Koster MJ, Warrington KJ (2017) Classification of large vessel vasculitis: can we separate giant cell arteritis from Takayasu arteritis? Presse Med 46(7–8 Pt 2):e205–e213CrossRef Koster MJ, Warrington KJ (2017) Classification of large vessel vasculitis: can we separate giant cell arteritis from Takayasu arteritis? Presse Med 46(7–8 Pt 2):e205–e213CrossRef
20.
Zurück zum Zitat Tuckwell K et al (2017) Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin Arthritis Rheum 46(5):657–664CrossRef Tuckwell K et al (2017) Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin Arthritis Rheum 46(5):657–664CrossRef
Metadaten
Titel
Giant cell arteritis associated with inflammatory bowel disease: a case-series and review of the literature
verfasst von
Delamo I. Bekele
Kenneth J. Warrington
Matthew J. Koster
Publikationsdatum
23.10.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 2/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04727-w

Weitere Artikel der Ausgabe 2/2021

Rheumatology International 2/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.